![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).
Lead Product(s): Debio 0123,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2024